Several studies based on the GEO database, next-generation transcriptome sequencing, and comprehensive bioinformatics analysis demonstrated that EMP2 is differentially expressed in lung cancer and normal lung tissues, and its transcription levels are significantly correlated with the survival rate of the adenocarcinoma subgroup [81, 82]. The gene discussed is EMP2; the disease is lung carcinoma.